Thread by @StephenVLiu

#ESMO20 Update on poziotinib in #HER2 mutant #NSCLC by Mark Socinski from the ongoing phase II ZENITH20 study. #LCSM @OncoAlert @AdventHealth

#ESMO20 There are 7 cohorts to ZENITH20, 3 have completed accrual. This presentation focuses on cohort 2, #HER2 mutant NSCLC. Heavily pretreated population with most having received IO therapy and some with prior HER2 therapy as well. #LCSM @OncoAlert

#ESMO20 Poziotinib in #HER2 mutant NSCLC had a response rate of 27.8%. Duration of response 5.1 months, median time on treatment 3.7 months, median PFS 5.5 months. #LCSM @OncoAlert

#ESMO20 Waterfall plot shows 74% of patients had some reduction. #LCSM

#ESMO20 Safety summary shows 87% had a dose interruption, 78% had a dose reduction. Diarrhea was common (82%) with 26% grade 3. Grade 3 rash in 30% and stomatitis in 22% (1 grade 4). Permanent discontinuation from AE in 12% of patients. #LCSM @OncoAlert

#ESMO20 Overall, poziotinib has some activity in #HER2 mutant NSCLC. RR 27.8% with median DOR of 5.1 months. Delivery limited by toxicity though, with frequent interruptions/dose reductions. The trial continues but with alternative dosing and BID schedule which may help. #LCSM